Cayman Miltefosine

Miltefosine is an inhibitor of CTP:phosphocholine cytidylyltransferase (CCT). It inhibits liposome-induced CCT activity in MDCK cell homogenates when used at concentrations ranging from 10 to 50 µM, as well as induces translocation of CCT from the cell membrane to the cytosol in MDCK cells. Miltefosine inhibits phosphatidylcholine biosynthesis induced by phorbol 12-myristate 13-acetate (PMA; Item No. ) in MDCK and HeLa cells when used at a concentration of 50 µM. It inhibits phosphatidylserine-activated PKC (IC₅₀ = 62 µM), as well as PMA-induced morphological changes and proliferation of MDCK cells. Miltefosine is active against clinical isolate promastigotes of L. infantum (EC₅₀s = 5-25 µM). Topical application of miltefosine (0.5%) completely eradicates L. amazonensis and induces re-epithelialization of lesions in a mouse model of cutaneous leishmaniasis. Formulations containing miltefosine have been used in the treatment of leishmaniasis and various free-living amoeba infections.

WARNING This product is not for human or veterinary use.